Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 5/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839763 | 0.89 | HDAC1 (0.53) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL839433 | 0.87 | MME (0.52) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL841539 | 0.87 | HDAC1 (0.51) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL840790 | 0.86 | LTB4R2 (0.62) | LTB4R2MMEAGTR1 | |
| SCHEMBL841257 | 0.85 | HDAC1 (0.54) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL6116943 | 0.82 | HDAC1 (0.49) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL840453 | 0.80 | LTB4R2 (0.50) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL841556 | 0.79 | LTB4R2 (0.42) | LTB4R2MMEAGTR1 | |
| SCHEMBL841346 | 0.78 | AGTR1 (0.45) | LTB4R2MMEAGTR1 | |
| SCHEMBL840125 | 0.78 | AGTR1 (0.45) | LTB4R2MMEAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8735625-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8143298-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7777077-B2 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | HDAC1 1285/4885HDAC6 2096/4885HDAC3 656/4885 |
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | HDAC1 1285/4885HDAC6 2096/4885HDAC3 656/4885 |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | HDAC1 1285/4885HDAC6 2096/4885HDAC3 656/4885 |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | MME, AGTR1, AGTR2 | HDAC1 1338/4885HDAC6 1532/4885HDAC3 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.